The Food and Drug Administration has approved Solaris Pharma’s Abbreviated New Drug Application for clindamycin phosphate EQ 1% topical gel, the first generic version of Clindagel® (Bausch Health).

Clindamycin phosphate EQ 1% gel is indicated for topical application in the treatment of acne vulgaris. The product contains 10mg of clindamycin, a lincosamide antibiotic, per gram in a gel vehicle.  Safety and effectiveness of the topical agent have not been established in children under 12 years of age.

The generic version is supplied in a 75mL bottle and is expected to be available immediately.


Solaris Pharma receives approval for first generic version of Clindagel® (clindamycin phosphate EQ 1%). News release. August 23, 2021.